Gene mutations affecting the expression and sequence of microglial genes (e.g. TREM2, CD33, and MS4A) increase risk for Alzheimer’s disease (AD), and implicate microglia in several disease pathways including toxic protein aggregation (Aβ and tau) and neuroinflammation5,6. This evidence concerns the gene MAPT and Alzheimer disease.